Itching clue: antibodies linked to immunotherapy side effect
NCT ID NCT05689463
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at 100 cancer patients who have had chronic itching for over a month while on immunotherapy drugs like pembrolizumab or nivolumab. Researchers want to see if certain antibodies (BP180 and BP230) in the blood are linked to the itching. The goal is to better understand this side effect, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify which patients are at risk of severe itching during immunotherapy, leading to better monitoring.
- What could go wrong
- This is an observational study with only 100 participants. It does not test a treatment, so it may not lead to direct changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH CHRONIC PRURITUS FOR MORE THAN 1 MONTH WHO HAVE RECEIVED IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UHRouen
RECRUITINGRouen, France